lobbying_activities: 2301336

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2301336	24f41c09-609b-415c-998b-d28bd2562574	Q2	POLSINELLI PC	314911	TEVA PHARMACEUTICALS USA, INC.	2019	second_quarter	PHA	H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act H.R.965/ S.340, CREATES Act H.R.1503, Orange Book Transparency Act H.R.1520, Purple Book Continuity Act H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2376/ S.1227, Prescription Pricing for the People Act S.1416, Affordable Prescriptions for Patients Act S.1895, Lower Health Care Costs Act H.R. 1499, Protecting Consumer Access to Generic Drugs Act Administration review of drug pricing policies	HOUSE OF REPRESENTATIVES,SENATE	75000		0	0	2019-07-11T10:40:32.103000-04:00